Bitcoin Holds Above $74,000 as Banks Brace for Decisions
Bitcoin holds above $74,000 as policymakers prepare to announce rate decisions this week, setting the tone for crypto...
Articles — Page 1823
Trump’s Iran Looks Improvised: The Finance Playbook
Markets toppled and surged in swings as investors assessed a policy path that some say appears improvised. Analysts w...
That Résumé Goes Right: Gen Z Interview Trend Sparks Debate
Investor Kevin O’Leary warns that bringing a parent to a job interview signals a loss of independence, insisting that...
Why Gas Prices Rise Even as U.S. World's Leading Producer
Gas prices are climbing despite the U.S. being the world's leading producer of oil. Industry officials point to refin...
Should Nvidia Stock While Under $200 Be a Smart Move?
Nvidia often dominates AI chip discussions, but a lower price doesn’t guarantee gains. This guide breaks down the ris...
Archer Aviation Investors Need to Watch This Risk Closely
Archer Aviation aims to redefine urban mobility, but a crowded risk landscape could derail the bull case. This deep d...
Team (TISI) 2025 Earnings: Q1 Insight and Takeaways
Team (TISI) kicks off 2025 with a solid Q1 showing that blends growing customer demand with margin challenges. This a...
Is Broadcom Stock Going $460? What Investors Should Know
Investors are weighing if broadcom stock going $460? is a plausible milestone. This guide breaks down the drivers, ri...
Funko (FNKO) 2025 Earnings: Revenue Growth and Outlook
Fans and investors alike crave clarity on Funko's 2025 earnings. This guide breaks down revenue streams, margin dynam...
What’s Behind Naspers’s Steady Exit From Remitly Today
Naspers is quietly reducing its Remitly exposure, a move that speaks to broader priorities than a single stock. This ...
VWOB BND: Which Bond ETF to Buy for Your Portfolio
If you’re weighing bond ETFs, VWOB and BND offer very different paths to fixed income. This guide breaks down costs, ...
This Promising GLP-1 Drug Could Renew Novo Nordisk Hope
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...